类风湿关节炎中活化外周血B细胞及其与抗TNF治疗和应答的关系:一项抗TNF对B细胞影响的随机临床试验
结果显示B细胞亚群在整个研究期间保持稳定,两治疗组临床应答无显著差异;多个活化B细胞群体在无应答者中频率较高,而过渡型B细胞频率较低。结论支持外周血B细胞亚群在RA中稳定,且活化B细胞与较弱应答相关。
要点
- 依那西普与阿达木单抗治疗24周期间外周血B细胞亚群保持稳定,记忆B细胞无显著变化。
- 双阻断TNF和LT(依那西普)与单阻断TNF(阿达木单抗)相比,临床应答无显著差异。
- 多个活化B细胞群体在无应答者中频率较高,过渡型B细胞频率较低。
核心结论
- 外周血B细胞亚群在RA中保持稳定,且不受依那西普双阻断TNF和LT或阿达木单抗单阻断TNF的差异影响。
- 活化B细胞与较弱的治疗应答相关。
研究设计与样本
- 随机临床试验,参与者按2:1比例随机接受依那西普(n=43)或阿达木单抗(n=20)标准剂量方案治疗24周。
- 纳入符合美国风湿病学会1987年RA分类标准、28关节疾病活动评分>4.4且接受稳定剂量甲氨蝶呤的患者。
- 主要机制终点为各治疗组从基线至第12周转换记忆B细胞比例的变化。
主要发现
- B细胞亚群在整个研究期间保持稳定,记忆B细胞无显著变化,与治疗组无关。
- 依那西普双阻断TNF和LT与阿达木单抗单阻断TNF相比,临床应答无显著差异。
- 多个活化B细胞群体(包括CD21-双阴性记忆B细胞和活化初始B细胞)的频率在无应答者所有时间点均较高。
- 接受抗TNF治疗的无应答者组中CD95+活化B细胞频率增加。
- 过渡型B细胞(推定调节性亚群)频率在无应答者中较低。
临床怎么用
- 外周血B细胞亚群检测可能有助于识别对抗TNF治疗应答较弱的RA患者。
- 活化B细胞频率较高和过渡型B细胞频率较低与较弱的治疗应答相关,可考虑作为应答预测的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: B cells can become activated in germinal center (GC) reactions in secondary lymphoid tissue and in ectopic GCs in rheumatoid arthritis (RA) synovium that may be tumor necrosis factor (TNF) and lymphotoxin (LT) dependent. This study was undertaken to characterize the peripheral B cell compartment longitudinally during anti-TNF therapy in RA. METHODS: Participants were randomized in a 2:1 ratio to receive standard dosing regimens of etanercept (n = 43) or adalimumab (n = 20) for 24 weeks. Eligible participants met the American College of Rheumatology 1987 criteria for RA, had clinically active disease (Disease Activity Score in 28 joints >4.4), and were receiving stable doses of methotrexate. The primary mechanistic end point was the change in switched memory B cell fraction from baseline to week 12 in each treatment group. RESULTS: B cell subsets remained surprisingly stable over the course of the study regardless of treatment group, with no significant change in memory B cells. Blockade of TNF and LT with etanercept compared to blockade of TNF alone with adalimumab did not translate into significant differences in clinical response. The frequencies of multiple activated B cell populations, including CD21- double-negative memory and activated naive B cells, were higher in RA nonresponders at all time points, and CD95+ activated B cell frequencies were increased in patients receiving anti-TNF treatment in the nonresponder group. In contrast, frequencies of transitional B cells-a putative regulatory subset-were lower in the nonresponders. CONCLUSION: Overall, our results support the notion that peripheral blood B cell subsets are remarkably stable in RA and not differentially impacted by dual blockade of TNF and LT with etanercept or single blockade of TNF with adalimumab. Activated B cells do associate with a less robust response.
引用
- Meednu N, Barnard J, Callahan K, et al. Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells. Arthritis Rheumatol. 2021. PMID: 34347945. doi:10.1002/art.41941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。